Preparation method of anagrelide hydrochloride diazacyclo impurity

Through the nucleophilic substitution and reduction cyclization reaction of Intermediate B, high-purity anagrel hydrochloride diazepyridine impurities were prepared, which solved the problem of low purity in the prior art, and achieved high-purity preparation and reference materials. Development ensures compliance with medicinal standards.

CN119039240APending Publication Date: 2024-11-29NANJING BIOZER PHARMATECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410976674.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-21
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The preparation method of anagrel hydrochloride diazole hydrochloride in the prior art has the problem of low purity and difficulty in achieving high purity preparation, which affects its use and content detection as a reference product.

Method used

The dissubstituted compound represented by formula I was obtained by nucleophilic substitution reaction of Intermediate B, and the reduction and cyclization reaction were carried out under heating conditions to produce high-purity anagrel hydrochloride diazepyridine impurity. The specific steps include Nucleophilic substitution reaction with ethyl bromoacetate under the action of alkaline, followed by reduction and cyclization reaction under a hydrogen atmosphere, using Pd/C catalyst and alcohol or tetrahydrofuran as solvents.

Benefits of technology

The high purity (to more than 90%) preparation of anagrel hydrochloride diazole impurities has been achieved, and the requirements for the development and content detection of reference materials in raw materials or preparations with pharmaceutical standards are met.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004954775850000011
    Figure BDA0004954775850000011
  • Figure BDA0004954775850000012
    Figure BDA0004954775850000012
  • Figure BDA0004954775850000013
    Figure BDA0004954775850000013
Patent Text Reader

Abstract

The invention relates to the technical field of medicines, in particular to a preparation method of an anagrelide hydrochloride diazacyclo impurity, which is characterized in that the impurity is prepared by the following steps: step 1, carrying out nucleophilic substitution reaction on an intermediate B to obtain a disubstituted compound as shown in a formula I; 2, the disubstituted compound shown in the formula I is further reduced and cyclized to prepare the new anagrelide hydrochloride dinitrogen heterocyclic impurity shown in the formula II, the high-purity anagrelide hydrochloride dinitrogen heterocyclic impurity with the purity reaching 90% or above can be obtained through the method, and the high-purity anagrelide hydrochloride dinitrogen heterocyclic impurity can be used as an anagrelide hydrochloride raw material or a reference substance in a preparation for method development or content detection; therefore, the prepared raw material medicine is ensured to meet the medicinal standard.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of medical technology, and in particular to a method for preparing anagrelide hydrochloride diazacyclic impurity. Background Art

[0002] Anagrelide hydrochloride is a cyclic adenosine monophosphate phosphodiesterase III inhibitor, which can inhibit the formation and aggregation of platelets at high concentrations. This drug was originally used to inhibit platelet aggregation and has an anti-thrombotic effect, but in recent years, it has been found to have a platelet-lowering effect when used at low doses. The mechanism of action is to affect the differentiation and maturation of megakaryocytes in the late cell cycle (after mitosis), thereby reducing platelet production. It does not affect the synthesis of DNA and RNA and the proliferation and division of megakaryocytes, and has no potential carcinogenicity.

[0003] The structure of anagrelide hydrochloride is shown below:

[0004]

[0005] At present, anagrelide hydrochloride is mainly synthesized by the following routes:

[0006]

[0007] The applicant discovered that in the process of preparing intermediate C, an amino disubstituted byproduct compound 1 shown in formula I was produced, and the structure is shown below:

[0008]

[0009] The compound of formula I is further reduced and cyclized to generate the anagrelide hydrochloride diazacyclic impurity shown in formula II, the structure of which is shown below:

[0010] Summary of the invention

[0011] The technical problem to be solved by the present invention is to provide a method for preparing a new impurity of anagrelide hydrochloride diazepine, so as to realize method development and content detection by using the high-purity anagrelide hydrochloride diazepine impurity as a reference substance.

[0012] In order to solve the above technical problems, the present invention provides a method for preparing anagrelide hydrochloride diazacyclic impurity shown in formula II, characterized in that the impurity is prepared by:

[0013] Step 1: Intermediate B is subjected to a nucleophilic substitution reaction to obtain a disubstituted compound of formula I;

[0014] Step 2: The disubstituted compound of formula I is further reduced and cyclized to obtain the anagrelide hydrochloride diazacyclic impurity of formula II;

[0015] The structures of intermediate B, formula I and formula II are as follows:

[0016]

[0017] In certain embodiments of the present invention, step 1 is to use intermediate B as a raw material, and react with ethyl bromoacetate in a solvent under the action of a base under heating conditions to produce a disubstituted compound of formula I.

[0018] In certain embodiments of the present invention, step 2 is to add a solvent to the disubstituted compound of formula I and a catalyst, replace with hydrogen, and carry out reduction and cyclization reaction under heating conditions and a hydrogen atmosphere to obtain the anagrelide hydrochloride diazacyclic impurity of formula II.

[0019] In certain embodiments of the present invention, a method for preparing anagrelide hydrochloride diazacyclic impurity shown in formula II, the synthetic route thereof is as follows:

[0020]

[0021] In certain embodiments of the present invention, the catalyst in step 2 is selected from Pd / C.

[0022] Preferably, the solvent in step 2 is selected from alcohol and tetrahydrofuran; preferably, the solvent is selected from methanol, ethanol or tetrahydrofuran.

[0023] Preferably, the mass percentage of the feed ratio of the catalyst in step 2 to the disubstituted compound shown in formula I is 5% to 25%, preferably 5% to 15%, such as 5%, 10%, 15%, 20%.

[0024] Preferably, the feed mass and volume ratio of the disubstituted compound represented by formula I in step 2 to the solvent is 1:15 to 1:5 mg / ml, such as 1:15, 1:10, or 1:5.

[0025] Preferably, the reaction temperature in step 2 is 40°C to the boiling point of the solvent, preferably 60°C to the boiling point of the solvent, such as 60°C, 70°C, 80°C, 90°C.

[0026] Preferably, the reaction time of step 2 is 2 to 48 h, preferably 6 to 24 h, preferably 6 to 18 h, preferably 6 to 10 h, such as 6 h, 8 h, 10 h.

[0027] In certain embodiments of the present invention, the base in step 1 is selected from potassium carbonate.

[0028] Preferably, the solvent in step 1 is acetonitrile, N,N-dimethylformamide or N-methylpyrrolidone.

[0029] Preferably, the molar feed ratio of intermediate B to potassium carbonate in step 1 is 1:2.5 to 1:8, preferably 1:3 to 1:6, such as 1:3, 1:4, 1:5, 1:6.

[0030] Preferably, the molar feed ratio of intermediate B to ethyl bromoacetate in step 1 is 1:2.5 to 1:6, preferably 1:3 to 1:5, such as 1:3, 1:4, 1:5.

[0031] Preferably, the mass volume ratio of intermediate B to solvent is 1:5 to 1:30 mg / ml, preferably 1:10 to 1:20 mg / ml, such as 1:10, 1:15, 1:20 mg / ml.

[0032] Preferably, the reaction temperature in step 1 is 40°C to the boiling point of the solvent, preferably 70°C to the boiling point of the solvent, such as 70°C, 80°C, 90°C, 100°C, etc.

[0033] Preferably, the reaction time of step 1 is 4 h to 72 h, preferably 12 h to 48 h, preferably 12 h to 36 h, such as 12 h, 18 h, 24 h, 30 h, 36 h.

[0034] The present invention also relates to the anagrelide hydrochloride diazacyclic impurity shown in formula II prepared by any of the above methods.

[0035] The present invention also relates to the use of the anagrelide hydrochloride diazacyclic impurity shown in formula II as a reference substance in anagrelide hydrochloride raw materials or preparations for method development or content detection.

[0036] The percentages in the examples are by mass unless otherwise specified.

[0037] Unless otherwise specified, all numbers used in this specification and claims to indicate content, concentration, ratio, weight, percentage, technical effect, etc. should be understood as modified by the term "about" or "approximately" in any case. "About" represents a range of ±10% of the value it modifies, preferably a range of ±5%.

[0038] Beneficial Effects

[0039] The invention has the advantages that the intermediate B of anagrelide hydrochloride is used as a raw material to prepare a new diazacyclic impurity of anagrelide hydrochloride, thereby solving the preparation problem of the diazacyclic impurity of anagrelide hydrochloride. The method can obtain high-purity diazacyclic impurity of anagrelide hydrochloride with a purity of more than 90%, which can be used as a reference substance in the raw material or preparation of anagrelide hydrochloride for method development or content detection, so as to ensure that the prepared raw material meets the pharmaceutical standards. DETAILED DESCRIPTION

[0040] The technical scheme of the present invention will be further described in detail below in conjunction with specific embodiments. It should be understood that the following embodiments are only exemplary descriptions and explanations of the present invention and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are included in the scope that the present invention is intended to protect.

[0041] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods.

[0042] Example 1

[0043] The preparation method of the diazacyclic impurity of anagrelide hydrochloride shown in formula II:

[0044]

[0045] Step 1: Add 5 g of intermediate B (19.42 mmol, 1 eq), 12.58 g (77.68 mmol, 4 eq) of ethyl bromoacetate, 16 g (116.5 mmol, 6 eq) of potassium carbonate and 100 ml (20 V) of acetonitrile into a single-mouth bottle, react at 70-80 ° C for 36 h, HPLC purity 73.03%; cool to room temperature, filter to remove inorganic salts; concentrate the filtrate to make sand, and purify it by column (petroleum ether / ethyl acetate = 20 / 1); concentrate the collected main fraction under reduced pressure to 2-3 V, and filter to obtain 4.9 g of compound I (yield: 55.3%).

[0046] Step 2: Add 3.5g of the compound of formula I, ethanol (35ml, 10V), and 0.35g of palladium carbon (10% w / w) into a three-necked flask; react at 90°C for 8h, and HPLC detection shows that the content of the compound of formula II is 10.52%; filter out the palladium carbon while hot, and stir the filtrate at 15-25°C until solid precipitates; filter, and rinse the filter cake with a small amount of ethanol; concentrate the filtrate to make sand, and purify it by column chromatography (petroleum ether / ethyl acetate=1 / 1, Rf=0.3) to obtain 90mg of a brown solid, which is the anagrelide hydrochloride diazacyclic impurity shown in formula II, with a purity of 94.68% and a yield of 3.2%. HNMR(DMSO-d)=1.18~1.21(t,3H), 3.32~3.35(d,2H), 3.46(s,1H), 4.06~4.13(m,4H), 7.06~7.08(d,1H), 7.57~7.59(d,1H), 10.23(s,1H), ESI m / z:[M+H] + =317.05.

[0047] Example 2

[0048] Step 2: Add 3.5 g of the compound of formula I, ethanol (35 ml, 10V), and 0.53 g of palladium carbon (15% w / w) into a three-necked flask; react at 90° C. for 6 h, and detect by HPLC that the content of the compound of formula II is 5.3%; filter out the palladium carbon while hot, and stir the filtrate at 15-25° C. until solid precipitates; filter, and rinse the filter cake with a small amount of ethanol; concentrate the filtrate to make sand, and purify by column chromatography (petroleum ether / ethyl acetate=1 / 1, Rf=0.3) to obtain anagrelide hydrochloride diazepine impurity shown in formula II.

[0049] Example 3

[0050] Step 2: Add 3.5 g of the compound of formula I, ethanol (35 ml, 10V), and 0.7 g of palladium carbon (20% w / w) into a three-necked flask; react at 90° C. for 6 h, and HPLC detection shows that the content of the compound of formula II is 4.9%; filter out the palladium carbon while hot, and stir the filtrate at 15-25° C. until solid precipitates; filter, and rinse the filter cake with a small amount of ethanol; concentrate the filtrate to make sand, and purify by column chromatography (petroleum ether / ethyl acetate=1 / 1, Rf=0.3) to obtain the anagrelide hydrochloride diazepine impurity shown in formula II.

[0051] Example 4

[0052] Step 2: Add 3.5 g of the compound of formula I, ethanol (17.5 ml, 5V), and 0.35 g of palladium carbon (10% w / w) into a three-necked flask; react at 90° C. for 6 h, and detect by HPLC that the content of the compound of formula II is 4.6%; filter out the palladium carbon while hot, and stir the filtrate at 15-25° C. until solid precipitates; filter, and rinse the filter cake with a small amount of ethanol; concentrate the filtrate to make sand, and purify by column chromatography (petroleum ether / ethyl acetate=1 / 1, Rf=0.3) to obtain anagrelide hydrochloride diazepine impurity shown in formula II.

[0053] Example 5

[0054] Step 2: Add 3.5 g of the compound of formula I, tetrahydrofuran (35 ml, 10V), and 0.17 g of palladium carbon (10% w / w) into a three-necked flask; react at 90° C. for 2 days, and HPLC detection shows that the content of the compound of formula II is 7.3%; filter out the palladium carbon while hot, and stir the filtrate at 15-25° C. until solid precipitates; filter, and rinse the filter cake with a small amount of ethanol; concentrate the filtrate to make sand, and purify by column chromatography (petroleum ether / ethyl acetate=1 / 1, Rf=0.3) to obtain anagrelide hydrochloride diazacyclic impurity shown in formula II.

[0055] Example 6

[0056] Step 1: Add 1g of intermediate B (3.88mmol, 1eq), 2.52g (4eq) of ethyl bromoacetate, 3.19g (6eq) of potassium carbonate and 20ml (20V) of acetonitrile into a single-mouth bottle, react at 70-80°C for 36h, HPLC purity 73%; cool to room temperature, filter to remove inorganic salts; concentrate the filtrate to make sand, and purify it by column (petroleum ether / ethyl acetate = 20 / 1); concentrate the collected main fraction under reduced pressure to 2-3V, and filter to obtain the compound of formula I.

[0057] Example 7

[0058] Step 1: Add 1 g of intermediate B (3.88 mmol, 1 eq), 2.52 g (4 eq) of ethyl bromoacetate, 3.19 g (6 eq) of potassium carbonate and 20 ml (20V) of DMF into a single-mouth bottle, react at 70-80°C for 36 h, HPLC purity 53%; cool to room temperature, filter to remove inorganic salts; concentrate the filtrate to make sand, and purify it by column (petroleum ether / ethyl acetate = 20 / 1); concentrate the collected main fraction under reduced pressure to 2-3V, and filter to obtain the compound of formula I.

[0059] Example 8

[0060] Step 1: Add 1 g of intermediate B (3.88 mmol, 1 eq), 2.52 g (4 eq) of ethyl bromoacetate, 3.19 g (6 eq) of potassium carbonate and 20 ml (20V) of NMP into a single-mouth bottle, react at 70-80°C for 36 h, HPLC purity 66%; cool to room temperature, filter to remove inorganic salts; concentrate the filtrate to make sand, and purify it by column (petroleum ether / ethyl acetate = 20 / 1); concentrate the collected main fraction under reduced pressure to 2-3V, and filter to obtain the compound of formula I.

[0061] Example 9

[0062] Step 1: Add 1 g of intermediate B (3.88 mmol, 1 eq), 1.58 g (2.5 eq) of ethyl bromoacetate, 1.32 g (2.5 eq) of potassium carbonate and 20 ml (20V) of acetonitrile into a single-mouth bottle, react at 70-80°C for 36 h, HPLC purity 34%; cool to room temperature, filter to remove inorganic salts; concentrate the filtrate to make sand, and purify it by column (petroleum ether / ethyl acetate = 20 / 1); concentrate the collected main fraction under reduced pressure to 2-3V, and filter to obtain the compound of formula I.

[0063] Example 10

[0064] Step 1: Add 1g of intermediate B (3.88mmol, 1eq), 1.89g (3eq) of ethyl bromoacetate, 1.59g (3eq) of potassium carbonate and 20ml (20V) of acetonitrile into a single-mouth bottle, react at 70-80°C for 36h, HPLC purity 44%; cool to room temperature, filter to remove inorganic salts; concentrate the filtrate to make sand, and purify it by column (petroleum ether / ethyl acetate = 20 / 1); concentrate the collected main fraction under reduced pressure to 2-3V, and filter to obtain the compound of formula I.

[0065] Embodiment 11

[0066] Step 1: Add 1g of intermediate B (3.88mmol, 1eq), 5.04g (6eq) of ethyl bromoacetate, 4.23g (8eq) of potassium carbonate and 30ml (30V) of acetonitrile into a single-mouth bottle, react at 70-80°C for 36h, HPLC purity 66%; cool to room temperature, filter to remove inorganic salts; concentrate the filtrate to make sand, and purify it by column (petroleum ether / ethyl acetate = 20 / 1); concentrate the collected main fraction under reduced pressure to 2-3V, and filter to obtain the compound of formula I.

[0067] Example 12

[0068] Step 1: Add 1g of intermediate B (3.88mmol, 1eq), 2.52g (4eq) of ethyl bromoacetate, 3.18g (6eq) of potassium carbonate and 5ml (5V) of acetonitrile into a single-mouth bottle, react at 70-80°C for 36h, HPLC purity 54%; cool to room temperature, filter to remove inorganic salts; concentrate the filtrate to make sand, and purify it by column (petroleum ether / ethyl acetate = 20 / 1); concentrate the collected main fraction under reduced pressure to 2-3V, and filter to obtain the compound of formula I.

[0069] Embodiment 13

[0070] Step 1: Add 1 g of intermediate B (3.88 mmol, 1 eq), 2.52 g (4 eq) of ethyl bromoacetate, 3.18 g (6 eq) of potassium carbonate and 10 ml (20 V) of acetonitrile into a single-mouth bottle, react at 40 ° C for 36 h, HPLC purity 12%; cool to room temperature, filter to remove inorganic salts; concentrate the filtrate to make sand, and purify it by column (petroleum ether / ethyl acetate = 20 / 1); concentrate the collected main fraction under reduced pressure to 2-3 V, and filter to obtain the compound of formula I.

[0071] Comparative Example 1

[0072] Step 1: Add 2 g of intermediate B, 2.6 g (2 eq) of ethyl bromoacetate, 1.6 g (2 eq) of sodium carbonate and 20 ml (10V) of acetonitrile into a single-necked bottle; react at 70° C. for 6 h. HPLC detection showed that the content of the compound of formula I was 27.25%.

[0073] Comparative Example 2

[0074] Step 1: Add 2 g of intermediate B, 2.6 g (2 eq) of ethyl bromoacetate, 3.2 g (4 eq) of sodium bicarbonate and 20 ml (10 V) of acetonitrile into a single-necked bottle; react at 70° C. for 6 h. HPLC detection showed that the content of the compound of formula I was 22.86%.

[0075] Comparative Example 3

[0076] An attempt was made to prepare a compound of formula II from a compound of formula III:

[0077]

[0078] Step 1: Add 0.1 g of compound III, 1 ml of tetrahydrofuran and 1 ml of 2M lithium hydroxide solution into a three-necked flask; react at 50°C for 2 h; use 2N dilute hydrochloric acid at pH = 2-3; add 1 ml of ethyl acetate and 1 ml of water, and stir for 10 min; separate the layers, wash the organic phase with 1 ml of brine; concentrate the organic phase under reduced pressure to obtain 0.45 g of a light yellow oil, with a yield of 54%.

[0079] Step 2: Add the above oil (1 eq), 0.30 g (1 eq) DCC, 10 mg DMAP and 4.5 ml DMF into a three-necked flask; stir at 40° C. for 0.5 h and then raise the temperature to 80° C. for 2 h; no compound of formula II was detected under HPLC monitoring.

[0080] The above is an explanation of the exemplary embodiments of the present invention. However, the protection scope of the present invention is not limited to the above embodiments. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A method for preparing anagrelide hydrochloride diazacyclic impurity represented by formula II, Features: The impurities are passed through: Step 1: Intermediate B is subjected to a nucleophilic substitution reaction to obtain a disubstituted compound of formula I; Step 2: The disubstituted compound of formula I is further reduced and cyclized to obtain the anagrelide hydrochloride diazacyclic impurity of formula II; The structures of intermediate B, formula I and formula II are as follows:

2. The preparation method according to claim 1, It is characterized in that Step 1 is to use intermediate B as a raw material, and to react with ethyl bromoacetate in a solvent under the action of a base and under heating conditions to produce a disubstituted compound shown in formula I.

3. The preparation method according to claim 1, It is characterized in that Step 2 is to add a solvent to the disubstituted compound and a catalyst shown in formula I, replace with hydrogen, and carry out reduction and cyclization reaction under heating conditions and a hydrogen atmosphere to obtain the anagrelide hydrochloride diazacyclic impurity shown in formula II.

4. The preparation method according to claim 1, wherein the synthetic route is as follows:

5. The preparation method according to claim 4, Features: The catalyst in step 2 is selected from Pd / C; Preferably, the solvent in step 2 is selected from alcohol and tetrahydrofuran; preferably, the solvent is selected from methanol, ethanol or tetrahydrofuran; Preferably, the mass percentage of the feed ratio of the catalyst in step 2 to the disubstituted compound represented by formula I is 5% to 25%, preferably 5% to 15%; Preferably, the feed mass and volume ratio of the disubstituted compound represented by formula I in step 2 to the solvent is 1:15 to 1:5 mg / ml; Preferably, the reaction temperature in step 2 is 40°C to the boiling point of the solvent, preferably 60°C to the boiling point of the solvent; Preferably, the reaction time of step 2 is 2 to 48 h, preferably 6 to 24 h, preferably 6 to 18 h, preferably 6 to 10 h.

6. The preparation method according to claim 4, Features: The base in step 1 is selected from potassium carbonate; Preferably, the solvent in step 1 is acetonitrile, N,N-dimethylformamide or N-methylpyrrolidone; Preferably, the molar feed ratio of intermediate B to potassium carbonate in step 1 is 1:2.5 to 1:8, preferably 1:3 to 1:6; Preferably, the molar feed ratio of intermediate B to ethyl bromoacetate in step 1 is 1:2.5 to 1:6, preferably 1:3 to 1:5; Preferably, the mass volume ratio of intermediate B to solvent is 1:5 to 1:30 mg / ml, preferably 1:10 to 1:20 mg / ml; Preferably, the reaction temperature in step 1 is 40°C to the boiling point of the solvent, preferably 70°C to the boiling point of the solvent; Preferably, the reaction time of step 1 is 4 h to 72 h, preferably 12 h to 48 h, preferably 12 h to 36 h.

7. The anagrelide hydrochloride diazacyclic impurity shown in formula II prepared by the method of claim 1.

8. Use of the diazacyclic impurity of anagrelide hydrochloride represented by formula II as a reference substance in anagrelide hydrochloride raw materials or preparations for method development or content detection.